Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DAGLA | Q9Y4D2 | 6/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.40 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7469486 | 0.79 | HSD11B1 (0.45) | HSD11B1DAGLAABHD6CCR3 | |
| SCHEMBL8416614 | 0.77 | HSD11B1 (0.45) | HSD11B1DPP4DAGLAABHD6ATM | |
| Hydrochloric Acid SCHEMBL6338784 | 0.77 | HTT (0.44) | HSD11B1CCR3 | |
| SCHEMBL5711730 | 0.73 | HSD11B1 (0.46) | HSD11B1DAGLAABHD6CCR3 | |
| SCHEMBL4151234 | 0.72 | MC4R (0.43) | HSD11B1 | |
| SCHEMBL17729937 | 0.71 | HCRTR1 (0.53) | DAGLAABHD6 | |
| SCHEMBL11129998 | 0.71 | HSD11B1 (0.44) | HSD11B1DAGLAABHD6CCR3 | |
| SCHEMBL350911 | 0.71 | HSD11B1 (0.48) | HSD11B1DPP4DAGLAABHD6 | |
| SCHEMBL27304337 | 0.71 | HSD11B1 (0.45) | HSD11B1DPP4DAGLAABHD6 | |
| SCHEMBL7413375 | 0.71 | HSD11B1 (0.45) | HSD11B1DAGLAABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0703221-B1 | 5 alpha-reductase Inhibitors | LILLY CO ELI (US) | 2002-03-27 | — | — | EP | disclosed |
| US-6150375-A | INHIBITORS OF BOTH OF THE HUMAN 5AR ISOZYMES; BENIGN PROSTATE HYPERPLASIA, MALE PATTERN BALDNESS, ACNE VULGARIS, SEBORRHEA, ANDROGENIC ALOPECIA, HIRSUTISM AND PROSTATE CANCER; BLOCKS THE CONVERSION OF TESTOSTERONE TO 5-ALPHA-DIHYDROTESTOSTERONE | ELI LILLY AND COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| US-5670514-A | BENZOQUINOLIN-3-ONE | ELI LILLY AND COMPANY (US) | 1997-09-23 | — | — | US | disclosed |
| US-5635197-A | BENZO(F)QUINOLIN-3-ONES; ANTICARCINOGENIC AGENTS; BONE DISORDERS | ELI LILLY AND COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| US-5629007-A | USING BENZOQUINOLIN-3-ONE DERIVATIVES | ELI LILLY AND COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| US-5622961-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5622962-A | PROSTATE CANCER, SKIN DISORDERS, BALDNESS | ELI LILLY AND COMPANY (US) | 1997-04-22 | — | — | US | disclosed |
| US-5578724-A | INHIBITORS OF 5-ALPHA-REDUCTASE | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| EP-0742010-A2 | Benzoquinolin-3-ones to inhibit bone loss | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| EP-0733365-A2 | Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer | ELI LILLY AND COMPANY (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5550134-A | ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1996009046-A1 | 5α-REDUCTASE INHIBITORS | ELI LILLY AND COMPANY (US) | 1996-03-28 | — | — | WO | disclosed |
| EP-0703221-A1 | 5 alpha-reductase Inhibitors | ELI LILLY AND COMPANY (US) | 1996-03-27 | — | — | EP | disclosed |